Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hillmen

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|July 31, 2021
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemiaH Parry, G McIlroy, R Bruton, et al.
Leukemia|February 3, 2012
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaS Pospisilova, D Gonzalez, J Malcikova, et al.
Leukemia|March 25, 2017
Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLLD R Howard, T Munir, L McParland, et al.
Blood Cancer Journal|February 4, 2017
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE studyM Montillo, S O'Brien, A Tedeschi, et al.
Leukemia|October 9, 2012
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLLA C Rawstron, S Böttcher, R Letestu, et al.
Leukemia|March 28, 2015
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemiaC Parrish, G B Scott, G Migneco, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Blood Cancer Journal|March 12, 2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trialA Bühler, C-M Wendtner, T J Kipps, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|July 31, 2021
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemiaH Parry, G McIlroy, R Bruton, et al.
Leukemia|February 3, 2012
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaS Pospisilova, D Gonzalez, J Malcikova, et al.
Leukemia|March 25, 2017
Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLLD R Howard, T Munir, L McParland, et al.
Blood Cancer Journal|February 4, 2017
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE studyM Montillo, S O'Brien, A Tedeschi, et al.
Leukemia|October 9, 2012
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLLA C Rawstron, S Böttcher, R Letestu, et al.
Leukemia|March 28, 2015
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemiaC Parrish, G B Scott, G Migneco, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Blood Cancer Journal|March 12, 2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trialA Bühler, C-M Wendtner, T J Kipps, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Pageof 6